ArticleMolecular biotechnology2024

SMYD2 Imparts Gemcitabine Resistance to Pancreatic Adenocarcinoma Cells by Upregulating EVI2A.

Lei Jin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.